Table 1. Treatment-related adverse events.

	Camrelizumab plus chemotherapy (n=205)		Chemotherapy alone (n=207)
	All grades	Grade ≥3	All grades	Grade ≥3
Any	204 (99.5%)	146 (71.2%)	199 (96.1%)	102 (49.3%)
Hematological toxicities
Neutrophil count decreased	148 (72.2%)	81 (39.5%)	133 (64.3%)	64 (30.9%)
WBC decreased	146 (71.2%)	41 (20.0%)	133 (64.3%)	30 (14.5%)
Anemia	139 (67.8%)	41 (20.0%)	125 (60.4%)	23 (11.1%)
Platelet count decreased	97 (47.3%)	34 (16.6%)	79 (38.2%)	24 (11.6%)
Lymphocyte count decreased	23 (11.2%)	9 (4.4%)	22 (10.6%)	5 (2.4%)
Hemoglobin decreased	20 (9.8%)	3 (1.5%)	22 (10.6%)	2 (1.0%)
Non-hematological toxicities
RCCEP	158 (77.1%)	4 (2.0%)	2 (1.0%)	0
AST increased	96 (46.8%)	4 (2.0%)	68 (32.9%)	2 (1.0%)
ALT increased	90 (43.9%)	10 (4.9%)	79 (38.2%)	6 (2.9%)
Nausea	75 (36.6%)	2 (1.0%)	61 (29.5%)	2 (1.0%)
Asthenia	68 (33.2%)	7 (3.4%)	58 (28.0%)	3 (1.4%)
Decreased appetite	66 (32.2%)	5 (2.4%)	56 (27.1%)	5 (2.4%)
Constipation	45 (22.0%)	0	35 (16.9%)	1 (0.5%)
Vomiting	44 (21.5%)	2 (1.0%)	35 (16.9%)	4 (1.9%)
Hepatic function abnormal	43 (21.0%)	4 (2.0%)	32 (15.5%)	1 (0.5%)
GGT increased	39 (19.0%)	6 (2.9%)	18 (8.7%)	1 (0.5%)
Blood creatinine increased	32 (15.6%)	1 (0.5%)	14 (6.8%)	1 (0.5%)
Rash	29 (14.1%)	4 (2.0%)	11 (5.3%)	0
Pruritus	25 (12.2%)	1 (0.5%)	3 (1.4%)	0
Edema peripheral	24 (11.7%)	0	17 (8.2%)	0
Myelosuppression	24 (11.7%)	14 (6.8%)	10 (4.8%)	4 (1.9%)
Blood bilirubin increased	23 (11.2%)	2 (1.0%)	14 (6.8%)	0
Hypothyroidism	23 (11.2%)	1 (0.5%)	0	0

Data are n (%). Treatment-related adverse events occurring in at least 10% of patients in either group are listed. Safety data for the chemotherapy alone group did not include data from the crossover phase.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferaseRCCEP, reactive cutaneous capillary endothelial proliferation; WBC, white blood cell